<DOC>
	<DOCNO>NCT02446171</DOCNO>
	<brief_summary>This clinical study open-label , randomize , 4-period , 4-treatment , crossover , single-center , single-dose bioavailability study alternate method administration crush naloxegol tablet , 25 mg naloxegol solution formulation , 25 mg , compare whole naloxegol tablet , 25 mg , healthy subject . The main objective study determine bioavailability three alternative method naloxegol administration compare whole naloxegol tablet give orally assessment primary pharmacokinetic ( PK ) parameter naloxegol</brief_summary>
	<brief_title>A Bioavailability Study With Alternate Methods Administration Naloxegol Tablets , Solution</brief_title>
	<detailed_description>This open-label , randomize , 4-period , 4-treatment , crossover , single-center , single-dose bioavailability study alternate method administration naloxegol : crush suspended water administer orally ( Treatment A ) , crush suspended water administer via nasogastric tube ( Treatment B ) , solution administer orally ( Treatment C ) tablet swallow whole ( Treatment D ) . Alternative way administer tablet may useful help patient , different reason , difficulty swallow whole tablet . Administration disperse ( crush ) tablet suspended water common way administer drug patient . A useful method patient whose condition prevent swallow administration disperse tablet nasogastric tube . Additionally solution formulation may attractive option patient include pediatric population . The main aim clinical study investigate whether blood concentration naloxegol ( pharmacokinetic ) treatment A , B C comparable treatment D. Additionally , safety tolerability shall assess .</detailed_description>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Naloxegol</mesh_term>
	<criteria>Healthy male female subject age 18 55 year suitable vein cannulation repeat venipuncture . Females must negative pregnancy test screen admission clinical unit , must lactate must non childbearing potential , confirm screen fulfil one follow criterion : Postmenopausal define amenorrhea least 12 month follow cessation exogenous hormonal treatment folliclestimulating hormone ( FSH ) level postmenopausal range . Documentation irreversible surgical sterilization hysterectomy , bilateral oophorectomy bilateral salpingectomy ; tubal ligation . Have body mass index ( BMI ) 18.5 29.9 kg/m2 inclusive weigh least 50 kg 100 kg inclusive . Able understand , read speak German language . History clinically significant disease disorder , opinion investigator , may either put potential subject risk participation study , influence result potential subject 's ability participate study . Current smoker smoke used nicotine product within previous 3 month . Use drug enzymeinducing property St John 's Wort within 3 week prior first administration IMP . Drugs include know CYP3A4 and/or Pgp inhibitor inducer , e.g. , diltiazem , verapamil , erythromycin Use prescribe nonprescribed medication include antacid , analgesic ( paracetamol/acetaminophen ) , herbal remedy , megadose vitamin ( intake 20 600 time recommended daily dose ) mineral 2 week prior first administration IMP long medication long halflife . For female , hormonal replacement therapy allow . Subject relevant history suicide attempt suicidal behavior . Any recent suicidal ideation within last 6 month ( level 4 5 ) , significant risk commit suicide , judge investigator use ColumbiaSuicide Severity Rating Scale ( CSSRS ) . Applicable subject willing participate genetic research : Nonleukocyte deplete whole blood transfusion within 120 day date genetic sample collection previous bone marrow transplant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>naloxegol tablet crush</keyword>
	<keyword>naloxegol oral solution</keyword>
	<keyword>naloxegol whole tablet</keyword>
	<keyword>relative bioavailability</keyword>
	<keyword>Phase I</keyword>
	<keyword>healthy subject</keyword>
</DOC>